Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA’s divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks
4 Ways for Marketers To Differentiate Their Brands In The Rare-Disease Space
September 14, 2016
2:24 pm
Data analytics, relationship building, and improved patient support are the keys to differentiating your rare-disease drug brands, according to these four marketers.
Havas Health partners with data firm to find rare disease patients
The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA’s post-market drug tracking; WebMD denies acquisition talks
Shire said it will acquire Dyax, which markets Kalbitor; Citron doesn’t plan to release any additional allegations against Valeant; Myriad Genetics launches social-media campaign
Five things for pharma marketers to know: Wednesday, October 21, 2015